NASDAQ
15.05.25 | 16:40
4,430 US-Dollar
-1,99 % -0,090
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Olema Pharmaceuticals stock target cut to $28 by H.C. Wainwright | 2 | Investing.com | ||
| Di | Olema Oncology Reports First Quarter 2025 Financial and Operating Results | 19 | GlobeNewswire (Europe) | Pivotal Phase 3 OPERA-02 trial of palazestrant in combination with ribociclib in frontline metastatic breast cancer on track for initiation in 2025, supported by promising updated efficacy data from... ► Artikel lesen | |
| 02.05. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 119 | GlobeNewswire (Europe) | SAN FRANCISCO, May 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 25.04. | Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025 | 2 | GlobeNewswire (USA) | ||
| 02.04. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 93 | GlobeNewswire (Europe) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 25.03. | Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting | 4 | GlobeNewswire (USA) | ||
| 19.03. | HC Wainwright maintains $30 target on Olema Pharma stock | 1 | Investing.com | ||
| 18.03. | Olema Pharmaceuticals GAAP EPS of -$0.51 | 2 | Seeking Alpha | ||
| OLEMA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 18.03. | Olema Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 18.03. | Olema Pharmaceuticals, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 18.03. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results | 436 | GlobeNewswire (Europe) | Pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L metastatic breast cancer on track for top-line data in 2026Pivotal Phase 3 OPERA-02 trial of palazestrant in combination... ► Artikel lesen | |
| 06.03. | Olema Pharmaceuticals stock holds $30 target at H.C. Wainwright | 4 | Investing.com | ||
| 05.03. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.03. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 124 | GlobeNewswire (Europe) | SAN FRANCISCO, March 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 18.02. | Olema Oncology Appoints Shawnte M. Mitchell, J.D. as Chief Legal Officer and Corporate Secretary | 171 | GlobeNewswire (Europe) | SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 04.02. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 106 | GlobeNewswire (Europe) | SAN FRANCISCO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| 10.01. | Olema Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Olema Pharmaceuticals files mixed shelf offering | 1 | Seeking Alpha | ||
| 03.01. | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 196 | GlobeNewswire (Europe) | SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,85 | -0,67 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| CUREVAC | 3,012 | -0,66 % | CureVac Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| AMGEN | 237,90 | +1,32 % | Aktienmarkt: Kurs der Amgen-Aktie im Minus (234,3972 €) | Im US-amerikanischen Wertpapierhandel notiert die Amgen-Aktie zur Stunde ein wenig leichter. Zuletzt zahlten Investoren für die Aktie 262,26 US-Dollar. Für Inhaber von Amgen ist der heutige Handelstag... ► Artikel lesen | |
| NOVAVAX | 5,470 | +2,59 % | Novavax springt kräftig an - Quartalszahlen pulverisiert | Der US-Biotechkonzern Novavax hat am Donnerstagnachmittag seine Quartalszahlen vorgelegt und die Erwartungen der Analysten um Längen geschlagen. Vor allem bei dem Gewinn pro Aktie gab es eine enorm... ► Artikel lesen | |
| BIOGEN | 106,85 | -0,93 % | BIOGEN INC. - 8-K, Current Report | ||
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - F-1/A, Registration statement for certain foreign private issuers | ||
| VIKING THERAPEUTICS | 23,700 | -0,34 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25
Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 6,950 | -1,45 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,700 | -1,02 % | FDA awards BioCryst's Orladeyo NDA for paediatric HAE | ||
| SAREPTA THERAPEUTICS | 31,050 | -3,03 % | Sarepta Therapeutics' Elevidys Gets Approval In Japan To Treat Duchenne Muscular Dystrophy | WASHINGTON (dpa-AFX) - Sarepta Therapeutics, Inc. (SRPT), Tuesday said that the Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Elevidys for the treatment of Duchenne muscular... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,016 | +2,73 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 0,924 | -6,60 % | PacBio Board Independent Investigation Concludes Allegations Unsubstantiated | MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the "Special Committee") has concluded its independent... ► Artikel lesen | |
| EXELIXIS | 40,980 | +2,50 % | Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday | ||
| VAXART | 0,369 | +1,26 % | Vaxart, Inc.: Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority... ► Artikel lesen | |
| TEMPUS AI | 61,60 | -4,94 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen |
OLEMA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,430 Euro und damit -1,99 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OLEMA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.